Abel Murillo

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial

Mark Sulkowski, Christophe Hézode, Jan Gerstoft et al. · The Lancet · 2014 · 280 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +14

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

Deepak L. Bhatt, Philippe Gabríel Steg, Shamir R Mehta et al. · The Lancet · 2019 · 210 citations · Full text

Medicine, Cardiology, Pharmacotherapy +15

Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial

Shelagh B. Coutts, Sandeep Ankolekar, Ramana Appireddy et al. · The Lancet · 2024 · 125 citations · Full text

Medicine, Neurology, Cerebrovascular Surgery +11

Long-term Safety of Spinal Cord Stimulation Systems in A Prospective, Global Registry of Patients With Chronic Pain

Richard Rauck, Eric Loudermilk, Simon Thomson et al. · Pain Management · 2023 · 27 citations · Full text

Medicine, Neurosurgery, Pain Management +13

A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4

Bradley Vince, John M. Hill, Eric Lawitz et al. · Journal of Hepatology · 2014 · 23 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15